Retatrutide Vs Semaglutide
Retatrutide vs Semaglutide: Triple Agonist vs GLP-1
Published by Peptara Labs · Updated · How we research and check our pages
The short answer
Retatrutide vs semaglutide is a comparison of a three-receptor agonist against a single-receptor one. Retatrutide hits GLP-1, GIP, and glucagon receptors and reported a mean weight change of about -24.2% at 48 weeks in a phase 2 trial (Jastreboff et al., NEJM 2023). Semaglutide hits only the GLP-1 receptor and reported about -15.3 kg (roughly 15%) at 68 weeks in the STEP 1 trial (Wilding et al., NEJM 2021). These figures come from two separate trials, not one head-to-head study, so read them as context, not a direct race.
This page is general educational information, research-use framing only, not medical advice. Research-grade retatrutide is supplied for laboratory research only, not for human use.
What is the difference between retatrutide and semaglutide?
The core difference is receptor count and approval status: retatrutide activates three hormone receptors and is investigational, while semaglutide activates one and is approved.
Semaglutide is a GLP-1 receptor agonist, a single-target molecule that copies the gut hormone GLP-1 (Wilding et al., NEJM 2021; doi:10.1056/NEJMoa2032183). It is approved by the FDA for chronic weight management under the brand Wegovy and for type 2 diabetes as Ozempic. Retatrutide, development name LY3437943, is a single peptide engineered to activate three receptors at once: GLP-1, GIP, and glucagon (Coskun et al., Cell Metabolism 2022, PMID 35985340). It is investigational. As of 2026 no regulator has approved it, and outside a clinical trial it is a research compound, not a medicine. So the comparison is not just one hormone target versus three. It is also a mature, approved drug versus an earlier-stage one whose strongest published data come from a smaller phase 2 trial.
Retatrutide vs semaglutide: the comparison table
At a glance, retatrutide reported larger mean weight change in its trial, while semaglutide has the deeper evidence base and regulatory approval behind it.
| Feature | Retatrutide | Semaglutide |
|---|---|---|
| Mechanism | GLP-1 + GIP + glucagon triple agonist | GLP-1 receptor agonist (single) |
| Trial-reported mean weight change | About -24.2% at 48 weeks (highest dose group) | About -15.3 kg at 68 weeks (roughly 15%) |
| Key trial | Phase 2, 338 adults (Jastreboff, NEJM 2023) | STEP 1, phase 3, 1,961 adults (Wilding, NEJM 2021) |
| Evidence stage | Investigational, phase 3 ongoing | FDA-approved (Wegovy for weight, Ozempic for diabetes) |
| Half-life | About 6 days (Urva, Lancet 2022) | About 1 week (Wegovy FDA label) |
| Cardiovascular outcome data | Not yet reported | 20% reduction in major events (SELECT, Lincoff, NEJM 2023) |
| Most common side effects | Gastrointestinal (nausea, diarrhea, vomiting) | Gastrointestinal (nausea, diarrhea, vomiting) |
The rows above are drawn from separate trials. The weight-change row in particular is a cross-trial read: the two numbers were measured in different studies over different time frames, so the table lines them up for reference, it does not report a contest between them.
How does each one work?
Both act on the GLP-1 pathway, but retatrutide adds two more receptor arms that semaglutide does not touch.
Semaglutide's single mechanism is GLP-1 receptor activation. That slows how fast the stomach empties, acts on brain appetite centers so meals feel smaller, and improves glucose handling (Wilding et al., NEJM 2021). It is the mechanism that opened the modern weight-loss drug class. Retatrutide keeps that GLP-1 arm and layers on two more (Coskun et al., Cell Metabolism 2022, PMID 35985340). The GIP receptor arm, shared with tirzepatide, is thought to add to the appetite and metabolic effect. The glucagon receptor arm is the part that is unique here: glucagon signaling can raise energy expenditure and push fat use in the liver, so the design idea was to cut food intake while also nudging the body to spend and mobilize more energy. More receptor targets is the leading explanation researchers give for why retatrutide's trial numbers ran higher than a single-target drug's, though hitting more receptors can also broaden the side-effect and monitoring picture. Both molecules use a fatty acid chain that binds to albumin in the blood, which slows clearance (Coskun et al., Cell Metabolism 2022; Wegovy FDA label).
Retatrutide vs semaglutide for weight loss: what did the trials report?
In their separate trials, retatrutide reported a larger mean weight change than semaglutide, but the studies were not the same length or the same phase, so this is a cross-trial comparison.
Retatrutide's number comes from a phase 2 obesity trial (Jastreboff et al., NEJM 2023;389(6):514-526; doi:10.1056/NEJMoa2301972; PMID 37366315). It enrolled 338 adults with obesity, ran 48 weeks, and compared several dose groups against placebo. The least squares mean weight change at 48 weeks reached about -24.2% in the highest dose group versus about -2.1% on placebo. At 24 weeks the highest dose group was already at about -17.5%, and by 48 weeks about 83% of that group had lost at least 15% of body weight.
Semaglutide's number comes from STEP 1 (Wilding et al., NEJM 2021;384:989-1002; doi:10.1056/NEJMoa2032183; PMID 33567185), a phase 3 trial in 1,961 adults with overweight or obesity. Mean weight change was -15.3 kg versus -2.6 kg on placebo at week 68, and 50.5% of the semaglutide group reached at least a 15% loss.
Here is the honest read on the gap. Retatrutide's roughly 24% was reached in 48 weeks in a smaller phase 2 trial; semaglutide's roughly 15% was reached in 68 weeks in a much larger phase 3 trial. One reports a percentage of body weight, the other reports kilograms, and the doses, populations, and durations differ. The two results simply were not generated in the same study, so the difference is suggestive of retatrutide's potency but is not head-to-head proof. The trial that would settle it directly has not been published.
Which has stronger evidence, retatrutide or semaglutide?
Semaglutide has the deeper and more mature evidence base, including large phase 3 trials, regulatory approval, and a cardiovascular outcome trial. Retatrutide's strongest published data are still phase 2.
Semaglutide has been through multiple large phase 3 trials and is FDA-approved for both weight management and type 2 diabetes. It also has a dedicated cardiovascular outcome trial: SELECT (Lincoff et al., NEJM 2023;389(24):2221-2232; doi:10.1056/NEJMoa2307563; PMID 37952131) enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes, and reported that semaglutide cut major adverse cardiovascular events by about 20% (a primary event in 6.5% of the semaglutide group versus 8.0% of the placebo group, hazard ratio 0.80) over a mean follow-up of about 40 months. That kind of hard-outcome data does not yet exist for retatrutide. Retatrutide's headline weight figure is from a single phase 2 trial, with a large phase 3 program still running. So on evidence maturity, the scoreboard favors semaglutide clearly, even though retatrutide's early weight numbers are larger.
How do the side effects compare?
Both compounds report a similar side-effect signature dominated by gastrointestinal effects, most frequent early in the trials, though retatrutide adds glucagon-related monitoring.
For both drugs the most common reported adverse events are gastrointestinal: nausea, diarrhea, vomiting, and constipation, mostly mild to moderate and most frequent early in the trials (Wilding et al., NEJM 2021; Jastreboff et al., NEJM 2023). In the semaglutide obesity trials these GI effects were the leading adverse events. In retatrutide's phase 2 trial the same GI pattern held, adverse events led to stopping the drug in about 6% to 16% of participants (versus none on placebo), and the trial also reported dose-dependent increases in heart rate that peaked around 24 weeks and then declined (Jastreboff et al., NEJM 2023). Retatrutide's glucagon arm is a reason its trials watched blood sugar and heart rate closely; glucose control generally improved in the obesity trial, but glucagon signaling is why researchers monitor metabolic markers. These are findings measured in selected trial participants under supervision. They are not a safety guarantee. Long-term safety across a general population is exactly what the ongoing retatrutide phase 3 program is built to test.
What are the half-lives?
Both are long-acting. Retatrutide's half-life is about 6 days; semaglutide's is about 1 week.
Retatrutide's phase 1b multiple-ascending-dose study reported a half-life of about 6 days (Urva et al., Lancet 2022; doi:10.1016/S0140-6736(22)02033-5). Semaglutide's elimination half-life is about 1 week, and it is more than 99% bound to plasma albumin, which slows clearance (Wegovy FDA prescribing information). Both use the same design trick: a fatty acid chain that binds reversibly to albumin, a blood protein, so the body clears the molecule slowly. In practice the two half-lives are close enough that both take several weeks to clear after administration ends.
How do the two compare overall?
Retatrutide reported the larger weight change and adds an extra mechanism, while semaglutide has a deeper, approved evidence base with hard cardiovascular outcome data.
Semaglutide is the compound with FDA approval for weight management, a long published record, and a dedicated cardiovascular outcome trial behind it, so it is the more anchored, better-documented compound today. Retatrutide reported the larger mean weight change of the two, but that figure is from a smaller, shorter phase 2 trial, it has no approval, no hard-outcome data yet, and outside a clinical trial it is not a legally available medicine. If the question is really about the approved GIP plus GLP-1 dual agonist in the middle, that is tirzepatide, covered on the retatrutide vs tirzepatide and semaglutide vs tirzepatide pages.
The mixing arithmetic for a retatrutide research vial has a reconstitution calculator at peptidesvietnam.com.
Keep reading
Related research and verification
Questions about the terms on this page?
The glossary and primer linked above define the receptor words used in this comparison. Our work is with research compounds for laboratory study, never for human use. Our staff read WhatsApp messages and write back themselves.
Ask on WhatsAppRetatrutide Vs Semaglutide: FAQ
Is retatrutide better than semaglutide for weight loss?
In their separate trials retatrutide reported a larger mean weight change (about -24.2% at 48 weeks, Jastreboff et al., NEJM 2023) than semaglutide (about -15.3 kg, roughly 15%, at 68 weeks, Wilding et al., NEJM 2021). But there is no head-to-head trial, the two studies differed in length, phase, and dose, and semaglutide has far more mature evidence. So the numbers suggest retatrutide is more potent, they do not prove it in a direct comparison.
Has retatrutide been compared to semaglutide in a head-to-head trial?
No published head-to-head randomized trial of retatrutide against semaglutide exists as of 2026. Every figure comparing them, including on this page, comes from separate studies (Jastreboff et al., NEJM 2023; Wilding et al., NEJM 2021), so it is a cross-trial comparison, not a direct one.
What is the main mechanism difference between retatrutide and semaglutide?
Semaglutide activates one receptor, GLP-1 (Wilding et al., NEJM 2021). Retatrutide activates three: GLP-1, GIP, and glucagon (Coskun et al., Cell Metabolism 2022, PMID 35985340). The glucagon arm is unique to retatrutide and can raise energy expenditure, which is the leading explanation for its larger trial weight numbers.
Is retatrutide FDA approved like semaglutide?
No. Semaglutide is FDA-approved (Wegovy for weight management, Ozempic for type 2 diabetes). Retatrutide is investigational, still in phase 3 testing, and outside a clinical trial it is not a legally available medicine (Jastreboff et al., NEJM 2023).
Does semaglutide have heart benefit data that retatrutide lacks?
Yes, so far. The SELECT trial in 17,604 adults reported that semaglutide cut major cardiovascular events by about 20% versus placebo (6.5% vs 8.0%, hazard ratio 0.80) over about 40 months (Lincoff et al., NEJM 2023, PMID 37952131). Retatrutide does not yet have a published cardiovascular outcome trial.
How do the side effects of retatrutide and semaglutide compare?
Both are dominated by gastrointestinal effects: nausea, diarrhea, vomiting, and constipation, most frequent early in the trials (Wilding et al., NEJM 2021; Jastreboff et al., NEJM 2023). Retatrutide's phase 2 trial also reported dose-dependent heart rate increases and, because of its glucagon arm, close monitoring of blood sugar.
What are the half-lives of retatrutide and semaglutide?
Retatrutide's half-life is about 6 days (Urva et al., Lancet 2022, doi:10.1016/S0140-6736(22)02033-5) and semaglutide's is about 1 week (Wegovy FDA label). Both are long-acting because a fatty acid chain binds them to albumin in the blood, which slows clearance.
How does retatrutide compare to tirzepatide, the dual agonist in between?
Tirzepatide is the approved GIP plus GLP-1 dual agonist that sits between single-target semaglutide and triple-target retatrutide. Its pivotal obesity trial (SURMOUNT-1) reported up to about -22.5% mean weight change in the highest dose group (Jastreboff et al., NEJM 2022). See the retatrutide vs tirzepatide page for that breakdown.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. PMID 37366315.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247. doi:10.1016/j.cmet.2022.07.013. PMID 35985340.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563. PMID 37952131.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID 35658024.
- Novo Nordisk. WEGOVY (semaglutide) injection, prescribing information (pharmacokinetics: elimination half-life about 1 week; plasma protein binding greater than 99%). U.S. Food and Drug Administration label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022;400(10366):1869-1881. doi:10.1016/S0140-6736(22)02033-5.
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
General educational information only, research-use framing, not medical advice. Research material is for laboratory research only, not for human use.